+ Watch RTRX
on My Watchlist
Retrophin, Inc has been even more erratic than most of the biopharm during the derisk cycle that pulled many down after the group had had a somewhat "bubbling" experience. It doesn't take many like Puma Biotech that soared closed to 300% this week to get the attention of speculators. Valuing early stage biotechs is pretty nigh impossible, as you have to determine the cost to complete trials, funds available, dilution, chance of success, time to success, market of the product if successful, companies ability to get sold for instant/maximum profit, versus bringing their own product to market without the manufacturing and sells skills in-house.Retrophin has been especially volatile, and while my call is well in the green after only a few days, things could change tomorrow. Added to the chance of their drug portfolio, Retrophin has class action suits against it for not mentioning litigation against it in it's May 10-Q, yet $746k, or about 10% of assets was recently demanded. Small in the big scheme of things, but cash is precious at this stage of development.Retrophin doubled from $10 to the mid-20's from Feb to April, starting with purchasing privately held Manchester Pharmaceuticals. Two FDA approved products should give Retrophin moderate, but not sufficient cash flow to use on it's own products. It's development list is too long to cite, fairly rare indices. It's RE-001, a therapy for the treatment of duchenne muscular dystrophy, dropped it back down to the $10 range.Speculative, can't recommend. Caps play.
damn me i forgot to put a limit order...but still got the shares cheaper than the ceo
undervalued. CEO bot a lot shares at 15-18. Tremendous potential...
insider buying + good stock
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions